Gofar Stock(SH:600538)2025-01-16 09:13Revenue Projections - The company expects to achieve approximately 350 million CNY in revenue for 2024, a decrease of about 20 million CNY or 5% compared to the previous year[3]. Net Loss and Profit Expectations - The projected net loss attributable to the parent company for 2024 is approximately 89 million CNY, an increase of about 7 million CNY or 9% compared to the previous year's loss[4]. - The net profit attributable to the parent company after deducting non-recurring gains and losses is also expected to be around -89 million CNY, remaining flat compared to the previous year[4]. Factors Contributing to Loss - The main reasons for the projected loss include increased competition leading to higher expenses and longer payment terms, resulting in a credit impairment loss of approximately 6.5 million CNY[7]. - The subsidiary Guangzhou Gaosheng Biotechnology Co., Ltd. is expected to see a 30% decline in net profit due to intensified market competition[7]. - The pharmaceutical plant of the subsidiary Beihai Guofa Chuanshan Bio Co., Ltd. is projected to experience a revenue decline of about 25%, leading to an increased loss of approximately 6 million CNY[7]. - The company anticipates an investment loss of about 12 million CNY from its investment in the Nanjing Huada Gongying No. 1 Venture Capital Fund due to declines in stock prices of its portfolio companies[7]. Goodwill Impairment and Financial Data - The company plans to recognize goodwill impairment of approximately 60 million CNY based on current operating conditions and future forecasts[8]. - The financial data provided is preliminary and has not been audited by a registered accountant, with final figures to be disclosed in the audited annual report[11]. - The company confirms there are no significant uncertainties affecting the accuracy of this earnings forecast[10].